Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]
Serina Therapeutics, Inc. (SER)
Company Research
Source: Yahoo! Finance
its proprietary POZ Platform ™ drug delivery technology, today reported financial results for the quarter ended June 30, 2024 and provided business highlights. Recent Highlights ? Partnership with Enable Injections. The Company will develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse TM for the treatment of Parkinson's disease. The enFuse TM wearable technology from Enable is designed to overcome both IV infusion and other subcutaneous administration method shortcomings through fast, simple, and convenient delivery, benefiting patients, providers, as well as payers, with the ability for at home self-administration. The Company anticipates submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration with plans to initiate a Phase 1 clinical trial in advanced Parkinson's disease patients in 2025. ? Presentation of POZ-lipid immunogenicity data. The Company presented novel data on Serina's innovative POZ-lipid,
Show less
Read more
Impact Snapshot
Event Time:
SER
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SER alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SER alerts
High impacting Serina Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SER
News
- Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business HighlightsGlobeNewswire
- Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit [Yahoo! Finance]Yahoo! Finance
- Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics SummitGlobeNewswire
- Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation [Yahoo! Finance]Yahoo! Finance
SER
Sec Filings
- 9/24/24 - Form 4
- 9/20/24 - Form 4
- 9/16/24 - Form 4
- SER's page on the SEC website